Protalix BioTherapeutics (PLX) Reports Q4 EPS of $0.02
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.37 --0%
Revenue Growth %: -49.8%
Financial Fact:
NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED:: -0.07
Today's EPS Names:
ORPB, ONEG, NDLS, More
Revenue Growth %: -49.8%
Financial Fact:
NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED:: -0.07
Today's EPS Names:
ORPB, ONEG, NDLS, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q4 EPS of $0.02, versus ($0.04) reported last year. Revenue for the quarter came in at $3.8 million, versus $1.8 million reported last year.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- HCA Holdings (HCA) Tops Q2 EPS by 19c ; Offers Guidance
- Verizon Communications (VZ) Tops Q2 EPS by 2c, Misses on Revenue, Tops on Postpaid Adds
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
